SlideShare a Scribd company logo
1 of 8
Download to read offline
12 August 2014
1QFY15 Results Update | Sector: Consumer
Britannia Industries
Gautam Duggad (Gautam.Duggad@MotilalOswal.com); +91 22 3982 5404
Manish Poddar (Manish.Poddar@MotilalOswal.com); +91 22 3027 8029
BSE SENSEX S&P CNX
CMP: INR1,151 TP: INR1,320 Buy25,881 7,727
Bloomberg BRIT IN
Equity Shares (m) 119.9
M.Cap. (INR b) / (USD b) 138.0/2.3
52-Week Range (INR) 1,186/658
1, 6, 12 Rel. Per (%) 14/1/21
Financials & Valuation (INR Million)
Y/E MAR 2015E 2016E 2017E
Net Sales 71,470 82,683 98,062
EBITDA 7,047 8,369 10,117
Adj PAT 4,596 5,452 6,398
Adj.EPS(INR) 38.5 45.6 53.6
Gr. (%) 24.3 18.6 17.4
BV/Sh.(INR) 91.5 110.6 133.0
RoE (%) 46.1 45.2 44.0
RoCE (%) 56.8 58.1 61.5
P/E (x) 30.1 25.3 21.6
P/BV (x) 12.6 10.5 8.7
 Britannia Industries (BRIT) 1QFY15 results were ahead of estimates. Net sales grew
15.3% YoY to INR16.2b (est. INR15.7b), while EBITDA grew 21.5% YoY to INR1.4b
(est. INR1.38b) as margins expanded 50bp YoY to 8.8% (est. 8.8%). PAT registered
healthy 24.9% growth to INR1.08b (est. INR1.02b). We estimate volume growth of
6-7%, while improved product mix and price hikes accounted for the rest.
 Operating margins up 50bp: Gross margin contracted 230bp YoY to 38% driven by
raw material inflation. Savings in advertising spends (down 180bp YoY to 7.3%),
employee (down 70bp YoY to 2.7%) and other expenses (down 30bp YoY to 11%)
aided the EBITDA margin expansion of 50bp YoY to 8.8% (est. 8.8%). Thus, EBITDA
grew 21.5% YoY to INR1.4b (est. INR1.38b). Higher depreciation expense (up
60.5% YoY to INR245.5m) on account of new accounting standards (additional
charge of INR90m) impacted EBIT, which grew 15.7% YoY. While higher other
income (up 32.5% YoY) and lower interest expense (down 91.6% YoY) drove 22%
YoY growth in PBT. Savings in tax rate (down 160bp YoY to 29.3%) further aided
the 24.9% YoY PAT growth to INR1.08b (est. INR1.02b).
 Consolidated sales, EBITDA and Adj. PAT posted 15.1%, 23.4% and 27% YoY
growth respectively in 1QFY15. Gross margin (38.3%) contracted 220bp YoY, while
operating margins (8.8%) expanded 60bp during the quarter.
 Imputed subsidiary numbers: Subsidiary sales and PAT posted 13.3% and 82.8%
growth to INR1.5b and INR58m respectively.
 Valuation and view: As mentioned in our earlier notes (“We believe operating
margin expansion is sustainable as it is not completely dependent on raw material
cycle”). BRIT is benefiting from cost containment measures undertaken in the past
12-18 months, in our view. Maintain Buy with a revised target price of INR1,320
(SOTP: 28x standalone EPS + 14x subsidiary EPS).
Investors are advised to refer through disclosures made at the end of the Research Report.
12 August 2014 2
Britannia Industries
Healthy sales growth; Volume growth at 6-7% (in our view)
 Stand-alone sales grew 15.3% YoY to INR16.2b (est. INR5b); volume growth
estimated at 6-7% while realization and mix improvement contributed the rest.
 Consol sales posted 15.1% YoY growth while imputed subsidiary sales posted
growth of 13.3% YoY.
Sales 3% ahead of estimates
Source: Company, MOSL
230bp contraction in Gross margins led by RM inflation
Source: Company, MOSL
Cumulative operating savings of 280bp resulted in 50bp EBITDA margin expansion
Source: Company, MOSL
Standalone gross margins contract 230bp
 Standalone gross margin contracted 230bp to 38% led by inflation in key raw
materials. Margins have declined after five quarters.
 However savings in ad spends (down 180bp YoY to 7.3%), employee (down 70bp
YoY to 2.7%) and other expenses (down 30bp YoY to 11%) aided the EBITDA
margin expansion of 50bps YoY to 8.8% (est. 8.8%).
 Thus EBITDA grew 21.5% YoY to INR 1.4bn (est. INR 1.4b).
 Higher depreciation expenses (up 60.5%) impacted the EBIT which grew 15.7%
YoY. New accounting standards resulted in additional INR90m of depreciation
charge for the quarter.
 Other income expanded 32.5% YoY while interest costs declined 91.5% YoY. This
drove 22% YoY growth in PBT.
 160bps savings in tax rates to 29.3% further aided the 24.9% YoY PAT growth to
INR 1.08bn (est INR 1.02bn). Adjusting for the additional depreciation charge,
PAT would have grown 32% YoY
11.0
12.9
12.5
13.1
12.2
14.0
14.5
14.9
14.0
15.9
16.1
16.2
16.2
20.8
17.9
15.5 16.1
10.8
8.7
16.5
13.5 14.9 13.7
11.1
9.0
15.3
1QFY12
2QFY12
3QFY12
4QFY12
1QFY13
2QFY13
3QFY13
4QFY13
1QFY14
2QFY14
3QFY14
4QFY14
1QFY15
Net Sales (INR b) Sales growth (%)
34.4 35.5
36.8
40.3
39.4
37.2 38.0
29.8 30.1 31.2 31.4
32.0
30.7 29.1
29.2
4.6
6.5
4.3
5.4
8.3 8.6 8.1 8.8
1QFY12
2QFY12
3QFY12
4QFY12
1QFY13
2QFY13
3QFY13
4QFY13
1QFY14
2QFY14
3QFY14
4QFY14
1QFY15
Gross Margins (%) Overheads (%)
EBIDTA Margins (%)
7.4 7.8 7.0 8.4 8.1 7.8 8.5 8.4 9.0 8.2 8.2 7.0 7.3
8.4 8.3 8.7 8.5 9.2 8.3 9.1 8.2 8.3 9.0 9.0 8.4 8.3
11.2 10.5 11.7 12.5 12.3
10.5 11.1 10.7 11.2 10.9 10.5 11.3 11.0
1QFY12
2QFY12
3QFY12
4QFY12
1QFY13
2QFY13
3QFY13
4QFY13
1QFY14
2QFY14
3QFY14
4QFY14
1QFY15
Ad Spend (%) Conversion Cost (%) Other expenses (%)
12 August 2014 3
Britannia Industries
 Consolidated performance: Sales, EBITDA and Adj. PAT posted 15.1%, 23.4% and
27% YoY growth, respectively. Gross margins (38.3%) contracted 220bp YoY
while EBITDA margins (8.8%) expanded 60bp YoY
 Imputed subsidiary posted 13.3% sales growth and 82.8% PAT growth to
INR1.5b and INR 58m respectively.
Valuation and view
 Spike in commodity costs can impact margins given restricted ability to pass on
prices in view of underlying moderation in category growth. However, Britannia
is focusing on driving premium portfolio and cost containment in supply chain
costs, in our view. Thus we believe, margin is not completely a function of RM
fluctuations.
 We remain positive on Britannia as we expect the margin gains to sustain, aided
by portfolio premiumization and cost containment in supply chain costs.
 Retain Buy with a revised TP of INR1,320 (SOTP: 28x standalone EPS + 14x Subs
EPS).
12 August 2014 4
Britannia Industries
Story in charts
Revenues went up 12% in FY14
Source: Company, MOSL
Biscuits Indexed market growth
Source: Company, MOSL
Gross Margin expanded 230bp YoY in FY14
Source: Company, MOSL
While EBITDA margin expanded 260bp YoY
Source: Company, MOSL
PAT increased 63.8% in FY14
Source: Company, MOSL
Return ratios (x)
Source: Company, MOSL
31,122
34,014
42,235
49,742
55,644
62,321
71,470
82,683
98,062
20.4
9.3
24.2
17.8
11.9 12.0
14.7 15.7
18.6
FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E
Revenues (INR m) Revenue growth (%)
100
112
96
51
35
27
37
1QFY13
2QFY13
3QFY13
4QFY13
1QFY14
2QFY14
3QFY14
Indexed market growth
39.8
38.6
36.4
34.6
36.1
36.8
38.9
39.7
40.2
40.9
FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E
Gross Margin (%)
11.812.3
11.7
5.8
8.9 8.4
4.9
5.6 6.0 5.7
8.4 8.7 9.1 9.5
FY04
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
FY13
FY14
FY15E
FY16E
FY17E
EBITDA Margin (%)
2.0 1.4
1.3
2.0
2.3 3.8 4.6 5.5 6.4
9.8
-28.1
-10.3
57.2
14.7
63.8
20.0 18.6 17.4
FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E
PAT (INR m) PAT growth (%)
24.2 24.4
36.5
28.7
36.7
31.1
42.6 42.1 41.3 40.3
FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E
RoE (%)
12 August 2014 5
Britannia Industries
Britannia Industries: an investment profile
Company description
Britannia Industries (BRIT) is the market leader in the
biscuits category, with a market share of 38% (in value
terms).
Key investment arguments
 Biscuits have high sensitivity to income levels. The
increase in disposable income should result in
expansion in demand for biscuits, particularly in
rural areas.
 Reduction in excise duty, increasing capacity
utilization at Baddi and reduction in pack sizes will
drive volumes and result in improved profitability.
Key investment risks
 Limited flexibility to take pricing actions keeps
margins vulnerable.
 Biscuits is a highly elastic category, with high
sensitivity to any price increase. Intense
competition and price sensitivity makes it difficult
to pass on any price increase to consumers,
particularly in the Glucose segment.
 Rising competitive intensity from deep pocket and
well entrenched competitors.
Valuation and view
 The stock trades at 30.1x FY15E and 25.3x FY16E
earnings.
 Retain Buy with a Target price of INR1,320 (SOTP:
28x standalone EPS + 14x Subs EPS)
Sector view
 We have a cautiously optimistic view on the sector
on back of inflationary tendency in the economy,
which might impact volumes as well as profit
margins of companies.
 Companies with low competitive pressures and
broad product portfolios will be able to better
withstand any slowdown in a particular segment.
 Longer-term prospects bright, given rising incomes
and low penetration.
Comparative valuations
Britannia Dabur Colgate
P/E (x) FY15E 30.1 31.8 33.8
FY16E 25.3 27.0 29.0
P/BV (x) FY15E 12.6 10.7 23.3
FY16E 10.5 8.9 18.7
EV/Sales (x) FY15E 1.8 4.1 4.7
FY16E 1.6 3.5 4.0
EV/EBITDA (x) FY15E 18.9 24.9 29.7
FY16E 15.6 21.2 26.3
EPS: MOSL forecast v/s consensus (INR)
MOSL Consensus Variation
Forecast Forecast (%)
FY15 38.5 38.0 1.2
FY16 45.6 45.8 -0.4
Target price and recommendation
Current Target Upside Reco.
Price (INR) Price (INR) (%)
1,157 1,320 14.1 Buy
Shareholding pattern (%)
Jun-14 Mar-14 Jun-13
Promoter 50.8 50.8 50.9
DII 8.5 8.4 9.9
FII 20.5 20.1 19.5
Others 20.3 20.7 19.8
Notes: FII includes depository receipts
Stock performance (1-year)
12 August 2014 6
Britannia Industries
Financials and valuations
Income statement (INR Million)
Y/E Mar 2014 2015E 2016E 2017E
Net Sales 62,321 71,470 82,683 98,062
Change (%) 12.0 14.7 15.7 18.6
EBITDA 5,961 7,047 8,369 10,117
EBITDA Margin (%) 9.5 9.7 10.0 10.2
Depreciation 634 723 828 986
EBIT 5,328 6,324 7,541 9,131
Interest 54 43 39 32
Other Income 353 380 400 450
Extraordinary items 0 0 0 0
PBT 5,626 6,661 7,901 9,549
Tax 1,795 2,065 2,449 3,151
Tax Rate (%) 31.9 31.0 31.0 33.0
Reported PAT 3,832 4,596 5,452 6,398
Adjusted PAT 3,698 4,596 5,451 6,397
Change (%) 58.1 24.3 18.6 17.4
Min. Int. & Assoc. Share 0 0 0 0
Adj Cons PAT 3,832 4,596 5,452 6,398
Balance sheet (INR Million)
Y/E Mar 2014 2015E 2016E 2017E
Share Capital 239 239 239 239
Reserves 8,761 10,687 12,970 15,650
Net Worth 9,000 10,926 13,209 15,889
Debt 843 1,501 308 308
Deferred Tax 4 4 4 4
Total Capital Employed 9,843 12,427 13,517 16,197
Gross Fixed Assets 8,893 10,143 11,643 13,643
Less: Acc Depreciation -4,556 -5,279 -6,107 -7,093
Net Fixed Assets 4,337 4,864 5,536 6,550
Capital WIP 250 250 250 250
Investments 3,799 6,123 6,675 8,425
Current Assets 9,952 11,340 12,811 14,803
Inventory 5,037 5,718 6,201 7,355
Debtors 908 1,026 1,180 1,391
Cash & Bank 1,744 2,151 2,800 3,200
Loans & Adv, Others 2,264 2,446 2,630 2,858
Curr Liabs & Provns 8,499 10,154 11,758 13,835
Curr. Liabilities 6,043 6,968 7,978 9,330
Provisions 2,456 3,187 3,780 4,505
Net Current Assets 1,453 1,186 1,053 968
Total Assets 9,843 12,427 13,517 16,197
E: MOSL Estimates
Ratios
Y/E Mar 2014 2015E 2016E 2017E
Basic (INR)
EPS 31.0 38.5 45.6 53.6
Cash EPS 37.4 44.5 52.6 61.8
Book Value 75.3 91.5 110.6 133.0
DPS 14.8 19.2 22.8 26.8
Payout (incl. Div. Tax.) 53.7 58.1 58.1 58.1
Valuation(x)
P/E 37.4 30.1 25.3 21.6
Cash P/E 30.9 26.0 22.0 18.7
Price / Book Value 15.4 12.6 10.5 8.7
EV/Sales 2.1 1.8 1.6 1.3
EV/EBITDA 22.7 18.9 15.6 12.7
Dividend Yield (%) 1.3 1.7 2.0 2.3
Profitability Ratios (%)
RoE 46.4 46.1 45.2 44.0
RoCE 58.7 56.8 58.1 61.5
Turnover Ratios (%)
Asset Turnover (x) 6.9 6.5 6.4 6.7
Debtors (No. of Days) 5.3 5.2 5.2 5.1
Inventory (No. of Days) 29.1 28.9 27.1 27.1
Creditors (No. of Days) 35.3 35.8 35.8 35.6
Leverage Ratios (%)
Net Debt/Equity (x) 0.1 0.1 0.0 0.0
Cash flow statement (INR Million)
Y/E Mar 2014 2015E 2016E 2017E
OP/(Loss) before Tax 4,637 5,590 6,795 8,439
Depreciation 571 634 723 828
Others 353 380 400 450
Interest 54 43 39 32
Direct Taxes Paid 1,795 2,065 2,449 3,151
(Inc)/Dec in Wkg Cap 644 -674 -782 -485
CF from Op. Activity 3,068 5,171 6,212 7,019
(Inc)/Dec in FA & CWIP 1,250 1,250 1,500 2,000
(Pur)/Sale of Invt -755 2,324 551 1,751
Others 133 0 1 1
CF from Inv. Activity 629 3,574 2,052 3,752
Inc/(Dec) in Net Worth 0 0 0 0
Inc / (Dec) in Debt 40 658 -1,193 0
Interest Paid 0 0 0 0
Divd Paid (incl Tax) 1,189 2,058 2,670 3,168
CF from Fin. Activity -1,418 -1,189 -3,510 -2,868
Inc/(Dec) in Cash 1,021 408 649 400
Add: Opening Balance 722 1,744 2,151 2,800
Closing Balance 1,744 2,151 2,800 3,200
12 August 2014 7
Britannia Industries
N O T E S
12 August 2014 8
Britannia Industries
Disclosures
This research report has been prepared by MOSt to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This
report is for personal information of the select recipient and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to
invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been
furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into
account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable
for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and
investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur.
MOSt and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business
relationships with a significant percentage of the companies covered by our Research Department Our research professionals provide important input into our investment banking and other business selection
processes. Investors should assume that MOSt and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that
the research professionals who were involved in preparing this material may participate in the solicitation of such business. The research professionals responsible for the preparation of this document may
interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. Our research professionals are paid in part based on the
profitability of MOSt which include earnings from investment banking and other business. MOSt generally prohibits its analysts, persons reporting to analysts, and members of their households from
maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOSt generally prohibits its analysts and persons reporting to analysts from serving as an
officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading
strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with
the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest . MOSt and
its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in
any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or
lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.
Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its
affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to
hold MOSt or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The
information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOSt’s interpretation of the
data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not
intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOSt
and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its
affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of
its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of
merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.
Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its
contents.
MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of
Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.
Disclosure of Interest Statement BRITANNIA INDUSTRIES LTD
 Analyst ownership of the stock No
Analyst Certification
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or
will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible
for preparation of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.
Regional Disclosures (outside India)
This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to
law, regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions.
For U.K.
This report is intended for distribution only to persons having professional experience in matters relating to investments as described in Article 19 of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (referred to as "investment professionals"). This document must not be acted on or relied on by persons who are not investment professionals. Any investment or investment activity to
which this document relates is only available to investment professionals and will be engaged in only with such persons.
For U.S.
Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States.
In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state
laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein
are not available to or intended for U.S. persons.
This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional
investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major
institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as
amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has
entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be
executed within the provisions of this chaperoning agreement.
The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer,
MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research
analyst account.
For Singapore
Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors
Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore
to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time.
In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited:
Anosh Koppikar Kadambari Balachandran
Email:anosh.Koppikar@motilaloswal.com Email : kadambari.balachandran@motilaloswal.com
Contact(+65)68189232 Contact: (+65) 68189233 / 65249115
Office Address:21 (Suite 31),16 Collyer Quay,Singapore 04931
Motilal Oswal Securities Ltd
Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025
Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com

More Related Content

What's hot

Dabur India Q1FY15: Maintain neutral
 Dabur India Q1FY15: Maintain neutral Dabur India Q1FY15: Maintain neutral
Dabur India Q1FY15: Maintain neutralIndiaNotes.com
 
Com Hem - Interim Report Q2 2014 – Presentation
Com Hem - Interim Report Q2 2014 – PresentationCom Hem - Interim Report Q2 2014 – Presentation
Com Hem - Interim Report Q2 2014 – Presentationcomhemgroup
 
Leonardo 3Q/9M 2016 Results Presentation
Leonardo 3Q/9M 2016 Results PresentationLeonardo 3Q/9M 2016 Results Presentation
Leonardo 3Q/9M 2016 Results PresentationLeonardo
 
Ceat Q1FY15: Higher opex impact margins; Book profits
 Ceat Q1FY15: Higher opex impact margins; Book profits Ceat Q1FY15: Higher opex impact margins; Book profits
Ceat Q1FY15: Higher opex impact margins; Book profitsIndiaNotes.com
 
Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010Angel Broking
 
bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...
bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...
bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...finance13
 
Finmeccanica First Half 2015 results presentation
Finmeccanica First Half 2015 results presentationFinmeccanica First Half 2015 results presentation
Finmeccanica First Half 2015 results presentationLeonardo
 
Leonardo First Half 2016 results presentation
Leonardo First Half 2016 results presentationLeonardo First Half 2016 results presentation
Leonardo First Half 2016 results presentationLeonardo
 
Nestle Result Update
Nestle  Result UpdateNestle  Result Update
Nestle Result UpdateAngel Broking
 
Bhel ru4 qfy2010-280510
Bhel ru4 qfy2010-280510Bhel ru4 qfy2010-280510
Bhel ru4 qfy2010-280510Angel Broking
 
Financial Results for the Third Quarter of the Fiscal Year Ending March 2018
Financial Results for the Third Quarter of the Fiscal Year Ending March 2018Financial Results for the Third Quarter of the Fiscal Year Ending March 2018
Financial Results for the Third Quarter of the Fiscal Year Ending March 2018KDDI
 
Victrex - Full Year Results 2013
Victrex - Full Year Results 2013Victrex - Full Year Results 2013
Victrex - Full Year Results 2013Company Spotlight
 
2016 Strategy & Outlook
2016 Strategy & Outlook2016 Strategy & Outlook
2016 Strategy & OutlookTotal
 
Afm nroi project ppt
Afm nroi project pptAfm nroi project ppt
Afm nroi project pptAnoop Sharma
 

What's hot (16)

Dabur India Q1FY15: Maintain neutral
 Dabur India Q1FY15: Maintain neutral Dabur India Q1FY15: Maintain neutral
Dabur India Q1FY15: Maintain neutral
 
Com Hem - Interim Report Q2 2014 – Presentation
Com Hem - Interim Report Q2 2014 – PresentationCom Hem - Interim Report Q2 2014 – Presentation
Com Hem - Interim Report Q2 2014 – Presentation
 
Ashok Leyland
Ashok LeylandAshok Leyland
Ashok Leyland
 
csx Q1_2005
csx  Q1_2005csx  Q1_2005
csx Q1_2005
 
Leonardo 3Q/9M 2016 Results Presentation
Leonardo 3Q/9M 2016 Results PresentationLeonardo 3Q/9M 2016 Results Presentation
Leonardo 3Q/9M 2016 Results Presentation
 
Ceat Q1FY15: Higher opex impact margins; Book profits
 Ceat Q1FY15: Higher opex impact margins; Book profits Ceat Q1FY15: Higher opex impact margins; Book profits
Ceat Q1FY15: Higher opex impact margins; Book profits
 
Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010Finolex cables ru2 qfy2011-251010
Finolex cables ru2 qfy2011-251010
 
bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...
bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...
bristol myerd squibb Bristol-Myers Squibb Company Reports First Quarter 2008 ...
 
Finmeccanica First Half 2015 results presentation
Finmeccanica First Half 2015 results presentationFinmeccanica First Half 2015 results presentation
Finmeccanica First Half 2015 results presentation
 
Leonardo First Half 2016 results presentation
Leonardo First Half 2016 results presentationLeonardo First Half 2016 results presentation
Leonardo First Half 2016 results presentation
 
Nestle Result Update
Nestle  Result UpdateNestle  Result Update
Nestle Result Update
 
Bhel ru4 qfy2010-280510
Bhel ru4 qfy2010-280510Bhel ru4 qfy2010-280510
Bhel ru4 qfy2010-280510
 
Financial Results for the Third Quarter of the Fiscal Year Ending March 2018
Financial Results for the Third Quarter of the Fiscal Year Ending March 2018Financial Results for the Third Quarter of the Fiscal Year Ending March 2018
Financial Results for the Third Quarter of the Fiscal Year Ending March 2018
 
Victrex - Full Year Results 2013
Victrex - Full Year Results 2013Victrex - Full Year Results 2013
Victrex - Full Year Results 2013
 
2016 Strategy & Outlook
2016 Strategy & Outlook2016 Strategy & Outlook
2016 Strategy & Outlook
 
Afm nroi project ppt
Afm nroi project pptAfm nroi project ppt
Afm nroi project ppt
 

Similar to Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal

Godrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralGodrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralIndiaNotes.com
 
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
Vaibhav Global Q1FY15: Outlook continues to remain positive; HoldIndiaNotes.com
 
Jagran Prakashan Q2FY15: Buy for a target of Rs165
Jagran Prakashan Q2FY15: Buy for a target of Rs165Jagran Prakashan Q2FY15: Buy for a target of Rs165
Jagran Prakashan Q2FY15: Buy for a target of Rs165IndiaNotes.com
 
Stock Market Report For Investors -Sai Proficient
Stock Market Report For Investors -Sai ProficientStock Market Report For Investors -Sai Proficient
Stock Market Report For Investors -Sai Proficientsai proficient research
 
Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014IndiaNotes.com
 
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangZydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangIndiaNotes.com
 
Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410IndiaNotes.com
 
Dabur ru2 qfy2011-271010
Dabur ru2 qfy2011-271010Dabur ru2 qfy2011-271010
Dabur ru2 qfy2011-271010Angel Broking
 
Ht media ru2 qfy2011-281010
Ht media ru2 qfy2011-281010Ht media ru2 qfy2011-281010
Ht media ru2 qfy2011-281010Angel Broking
 
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldHSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldIndiaNotes.com
 
Jagran Prakashan Q1FY15: Buy
 Jagran Prakashan Q1FY15: Buy Jagran Prakashan Q1FY15: Buy
Jagran Prakashan Q1FY15: BuyIndiaNotes.com
 
Crompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buyCrompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buyIndiaNotes.com
 
Presentation Material for 3Q / Mar. 2020
Presentation Material for 3Q / Mar. 2020Presentation Material for 3Q / Mar. 2020
Presentation Material for 3Q / Mar. 2020RicohLease
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangIndiaNotes.com
 
NTPC Ltd.Q2FY Result Update
NTPC Ltd.Q2FY Result UpdateNTPC Ltd.Q2FY Result Update
NTPC Ltd.Q2FY Result Updatechoice broking
 
Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16choice broking
 
ING Vyasa Bank Q2FY14 Result: Maintain neutral
ING Vyasa Bank Q2FY14 Result: Maintain neutralING Vyasa Bank Q2FY14 Result: Maintain neutral
ING Vyasa Bank Q2FY14 Result: Maintain neutralIndiaNotes.com
 
Hul ru2 qfy2011-251010
Hul ru2 qfy2011-251010Hul ru2 qfy2011-251010
Hul ru2 qfy2011-251010Angel Broking
 
ITC 1QFY15 results largely in-line; buy
 ITC 1QFY15 results largely in-line; buy ITC 1QFY15 results largely in-line; buy
ITC 1QFY15 results largely in-line; buyIndiaNotes.com
 

Similar to Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal (20)

Godrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; NeutralGodrej Consumer's Q4 results were slightly below expectations; Neutral
Godrej Consumer's Q4 results were slightly below expectations; Neutral
 
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
Vaibhav Global Q1FY15: Outlook continues to remain positive; Hold
 
Jagran Prakashan Q2FY15: Buy for a target of Rs165
Jagran Prakashan Q2FY15: Buy for a target of Rs165Jagran Prakashan Q2FY15: Buy for a target of Rs165
Jagran Prakashan Q2FY15: Buy for a target of Rs165
 
Stock Market Report For Investors -Sai Proficient
Stock Market Report For Investors -Sai ProficientStock Market Report For Investors -Sai Proficient
Stock Market Report For Investors -Sai Proficient
 
Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014Motilal oswal dishtv_30oct_2014
Motilal oswal dishtv_30oct_2014
 
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal BangZydus Wellness reports a subdued quarter, hold - Nirmal Bang
Zydus Wellness reports a subdued quarter, hold - Nirmal Bang
 
Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410
 
Dabur ru2 qfy2011-271010
Dabur ru2 qfy2011-271010Dabur ru2 qfy2011-271010
Dabur ru2 qfy2011-271010
 
Ht media ru2 qfy2011-281010
Ht media ru2 qfy2011-281010Ht media ru2 qfy2011-281010
Ht media ru2 qfy2011-281010
 
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldHSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
 
Jagran Prakashan Q1FY15: Buy
 Jagran Prakashan Q1FY15: Buy Jagran Prakashan Q1FY15: Buy
Jagran Prakashan Q1FY15: Buy
 
Crompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buyCrompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buy
 
Presentation Material for 3Q / Mar. 2020
Presentation Material for 3Q / Mar. 2020Presentation Material for 3Q / Mar. 2020
Presentation Material for 3Q / Mar. 2020
 
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal BangQ2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
Q2FY15: Hold Mahindra & Mahindra Financial Services - Nirmal Bang
 
NTPC Ltd.Q2FY Result Update
NTPC Ltd.Q2FY Result UpdateNTPC Ltd.Q2FY Result Update
NTPC Ltd.Q2FY Result Update
 
Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16Akzo Nobel India- Result Analysis Q2FY16
Akzo Nobel India- Result Analysis Q2FY16
 
Britannia
BritanniaBritannia
Britannia
 
ING Vyasa Bank Q2FY14 Result: Maintain neutral
ING Vyasa Bank Q2FY14 Result: Maintain neutralING Vyasa Bank Q2FY14 Result: Maintain neutral
ING Vyasa Bank Q2FY14 Result: Maintain neutral
 
Hul ru2 qfy2011-251010
Hul ru2 qfy2011-251010Hul ru2 qfy2011-251010
Hul ru2 qfy2011-251010
 
ITC 1QFY15 results largely in-line; buy
 ITC 1QFY15 results largely in-line; buy ITC 1QFY15 results largely in-line; buy
ITC 1QFY15 results largely in-line; buy
 

More from IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15IndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaIndiaNotes.com
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesIndiaNotes.com
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoIndiaNotes.com
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityIndiaNotes.com
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16IndiaNotes.com
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtIndiaNotes.com
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...IndiaNotes.com
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...IndiaNotes.com
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CAREIndiaNotes.com
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...IndiaNotes.com
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16EIndiaNotes.com
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...IndiaNotes.com
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyIndiaNotes.com
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15IndiaNotes.com
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndiaNotes.com
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyIndiaNotes.com
 

More from IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16Grasim Industries reports improved performance in Q1FY16
Grasim Industries reports improved performance in Q1FY16
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15Nirmal pi industries_03_aug15
Nirmal pi industries_03_aug15
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 

Britannia Industries 1QFY15 results ahead of estimate; buy - Motilal Oswal

  • 1. 12 August 2014 1QFY15 Results Update | Sector: Consumer Britannia Industries Gautam Duggad (Gautam.Duggad@MotilalOswal.com); +91 22 3982 5404 Manish Poddar (Manish.Poddar@MotilalOswal.com); +91 22 3027 8029 BSE SENSEX S&P CNX CMP: INR1,151 TP: INR1,320 Buy25,881 7,727 Bloomberg BRIT IN Equity Shares (m) 119.9 M.Cap. (INR b) / (USD b) 138.0/2.3 52-Week Range (INR) 1,186/658 1, 6, 12 Rel. Per (%) 14/1/21 Financials & Valuation (INR Million) Y/E MAR 2015E 2016E 2017E Net Sales 71,470 82,683 98,062 EBITDA 7,047 8,369 10,117 Adj PAT 4,596 5,452 6,398 Adj.EPS(INR) 38.5 45.6 53.6 Gr. (%) 24.3 18.6 17.4 BV/Sh.(INR) 91.5 110.6 133.0 RoE (%) 46.1 45.2 44.0 RoCE (%) 56.8 58.1 61.5 P/E (x) 30.1 25.3 21.6 P/BV (x) 12.6 10.5 8.7  Britannia Industries (BRIT) 1QFY15 results were ahead of estimates. Net sales grew 15.3% YoY to INR16.2b (est. INR15.7b), while EBITDA grew 21.5% YoY to INR1.4b (est. INR1.38b) as margins expanded 50bp YoY to 8.8% (est. 8.8%). PAT registered healthy 24.9% growth to INR1.08b (est. INR1.02b). We estimate volume growth of 6-7%, while improved product mix and price hikes accounted for the rest.  Operating margins up 50bp: Gross margin contracted 230bp YoY to 38% driven by raw material inflation. Savings in advertising spends (down 180bp YoY to 7.3%), employee (down 70bp YoY to 2.7%) and other expenses (down 30bp YoY to 11%) aided the EBITDA margin expansion of 50bp YoY to 8.8% (est. 8.8%). Thus, EBITDA grew 21.5% YoY to INR1.4b (est. INR1.38b). Higher depreciation expense (up 60.5% YoY to INR245.5m) on account of new accounting standards (additional charge of INR90m) impacted EBIT, which grew 15.7% YoY. While higher other income (up 32.5% YoY) and lower interest expense (down 91.6% YoY) drove 22% YoY growth in PBT. Savings in tax rate (down 160bp YoY to 29.3%) further aided the 24.9% YoY PAT growth to INR1.08b (est. INR1.02b).  Consolidated sales, EBITDA and Adj. PAT posted 15.1%, 23.4% and 27% YoY growth respectively in 1QFY15. Gross margin (38.3%) contracted 220bp YoY, while operating margins (8.8%) expanded 60bp during the quarter.  Imputed subsidiary numbers: Subsidiary sales and PAT posted 13.3% and 82.8% growth to INR1.5b and INR58m respectively.  Valuation and view: As mentioned in our earlier notes (“We believe operating margin expansion is sustainable as it is not completely dependent on raw material cycle”). BRIT is benefiting from cost containment measures undertaken in the past 12-18 months, in our view. Maintain Buy with a revised target price of INR1,320 (SOTP: 28x standalone EPS + 14x subsidiary EPS). Investors are advised to refer through disclosures made at the end of the Research Report.
  • 2. 12 August 2014 2 Britannia Industries Healthy sales growth; Volume growth at 6-7% (in our view)  Stand-alone sales grew 15.3% YoY to INR16.2b (est. INR5b); volume growth estimated at 6-7% while realization and mix improvement contributed the rest.  Consol sales posted 15.1% YoY growth while imputed subsidiary sales posted growth of 13.3% YoY. Sales 3% ahead of estimates Source: Company, MOSL 230bp contraction in Gross margins led by RM inflation Source: Company, MOSL Cumulative operating savings of 280bp resulted in 50bp EBITDA margin expansion Source: Company, MOSL Standalone gross margins contract 230bp  Standalone gross margin contracted 230bp to 38% led by inflation in key raw materials. Margins have declined after five quarters.  However savings in ad spends (down 180bp YoY to 7.3%), employee (down 70bp YoY to 2.7%) and other expenses (down 30bp YoY to 11%) aided the EBITDA margin expansion of 50bps YoY to 8.8% (est. 8.8%).  Thus EBITDA grew 21.5% YoY to INR 1.4bn (est. INR 1.4b).  Higher depreciation expenses (up 60.5%) impacted the EBIT which grew 15.7% YoY. New accounting standards resulted in additional INR90m of depreciation charge for the quarter.  Other income expanded 32.5% YoY while interest costs declined 91.5% YoY. This drove 22% YoY growth in PBT.  160bps savings in tax rates to 29.3% further aided the 24.9% YoY PAT growth to INR 1.08bn (est INR 1.02bn). Adjusting for the additional depreciation charge, PAT would have grown 32% YoY 11.0 12.9 12.5 13.1 12.2 14.0 14.5 14.9 14.0 15.9 16.1 16.2 16.2 20.8 17.9 15.5 16.1 10.8 8.7 16.5 13.5 14.9 13.7 11.1 9.0 15.3 1QFY12 2QFY12 3QFY12 4QFY12 1QFY13 2QFY13 3QFY13 4QFY13 1QFY14 2QFY14 3QFY14 4QFY14 1QFY15 Net Sales (INR b) Sales growth (%) 34.4 35.5 36.8 40.3 39.4 37.2 38.0 29.8 30.1 31.2 31.4 32.0 30.7 29.1 29.2 4.6 6.5 4.3 5.4 8.3 8.6 8.1 8.8 1QFY12 2QFY12 3QFY12 4QFY12 1QFY13 2QFY13 3QFY13 4QFY13 1QFY14 2QFY14 3QFY14 4QFY14 1QFY15 Gross Margins (%) Overheads (%) EBIDTA Margins (%) 7.4 7.8 7.0 8.4 8.1 7.8 8.5 8.4 9.0 8.2 8.2 7.0 7.3 8.4 8.3 8.7 8.5 9.2 8.3 9.1 8.2 8.3 9.0 9.0 8.4 8.3 11.2 10.5 11.7 12.5 12.3 10.5 11.1 10.7 11.2 10.9 10.5 11.3 11.0 1QFY12 2QFY12 3QFY12 4QFY12 1QFY13 2QFY13 3QFY13 4QFY13 1QFY14 2QFY14 3QFY14 4QFY14 1QFY15 Ad Spend (%) Conversion Cost (%) Other expenses (%)
  • 3. 12 August 2014 3 Britannia Industries  Consolidated performance: Sales, EBITDA and Adj. PAT posted 15.1%, 23.4% and 27% YoY growth, respectively. Gross margins (38.3%) contracted 220bp YoY while EBITDA margins (8.8%) expanded 60bp YoY  Imputed subsidiary posted 13.3% sales growth and 82.8% PAT growth to INR1.5b and INR 58m respectively. Valuation and view  Spike in commodity costs can impact margins given restricted ability to pass on prices in view of underlying moderation in category growth. However, Britannia is focusing on driving premium portfolio and cost containment in supply chain costs, in our view. Thus we believe, margin is not completely a function of RM fluctuations.  We remain positive on Britannia as we expect the margin gains to sustain, aided by portfolio premiumization and cost containment in supply chain costs.  Retain Buy with a revised TP of INR1,320 (SOTP: 28x standalone EPS + 14x Subs EPS).
  • 4. 12 August 2014 4 Britannia Industries Story in charts Revenues went up 12% in FY14 Source: Company, MOSL Biscuits Indexed market growth Source: Company, MOSL Gross Margin expanded 230bp YoY in FY14 Source: Company, MOSL While EBITDA margin expanded 260bp YoY Source: Company, MOSL PAT increased 63.8% in FY14 Source: Company, MOSL Return ratios (x) Source: Company, MOSL 31,122 34,014 42,235 49,742 55,644 62,321 71,470 82,683 98,062 20.4 9.3 24.2 17.8 11.9 12.0 14.7 15.7 18.6 FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E Revenues (INR m) Revenue growth (%) 100 112 96 51 35 27 37 1QFY13 2QFY13 3QFY13 4QFY13 1QFY14 2QFY14 3QFY14 Indexed market growth 39.8 38.6 36.4 34.6 36.1 36.8 38.9 39.7 40.2 40.9 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E Gross Margin (%) 11.812.3 11.7 5.8 8.9 8.4 4.9 5.6 6.0 5.7 8.4 8.7 9.1 9.5 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E EBITDA Margin (%) 2.0 1.4 1.3 2.0 2.3 3.8 4.6 5.5 6.4 9.8 -28.1 -10.3 57.2 14.7 63.8 20.0 18.6 17.4 FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E PAT (INR m) PAT growth (%) 24.2 24.4 36.5 28.7 36.7 31.1 42.6 42.1 41.3 40.3 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15E FY16E FY17E RoE (%)
  • 5. 12 August 2014 5 Britannia Industries Britannia Industries: an investment profile Company description Britannia Industries (BRIT) is the market leader in the biscuits category, with a market share of 38% (in value terms). Key investment arguments  Biscuits have high sensitivity to income levels. The increase in disposable income should result in expansion in demand for biscuits, particularly in rural areas.  Reduction in excise duty, increasing capacity utilization at Baddi and reduction in pack sizes will drive volumes and result in improved profitability. Key investment risks  Limited flexibility to take pricing actions keeps margins vulnerable.  Biscuits is a highly elastic category, with high sensitivity to any price increase. Intense competition and price sensitivity makes it difficult to pass on any price increase to consumers, particularly in the Glucose segment.  Rising competitive intensity from deep pocket and well entrenched competitors. Valuation and view  The stock trades at 30.1x FY15E and 25.3x FY16E earnings.  Retain Buy with a Target price of INR1,320 (SOTP: 28x standalone EPS + 14x Subs EPS) Sector view  We have a cautiously optimistic view on the sector on back of inflationary tendency in the economy, which might impact volumes as well as profit margins of companies.  Companies with low competitive pressures and broad product portfolios will be able to better withstand any slowdown in a particular segment.  Longer-term prospects bright, given rising incomes and low penetration. Comparative valuations Britannia Dabur Colgate P/E (x) FY15E 30.1 31.8 33.8 FY16E 25.3 27.0 29.0 P/BV (x) FY15E 12.6 10.7 23.3 FY16E 10.5 8.9 18.7 EV/Sales (x) FY15E 1.8 4.1 4.7 FY16E 1.6 3.5 4.0 EV/EBITDA (x) FY15E 18.9 24.9 29.7 FY16E 15.6 21.2 26.3 EPS: MOSL forecast v/s consensus (INR) MOSL Consensus Variation Forecast Forecast (%) FY15 38.5 38.0 1.2 FY16 45.6 45.8 -0.4 Target price and recommendation Current Target Upside Reco. Price (INR) Price (INR) (%) 1,157 1,320 14.1 Buy Shareholding pattern (%) Jun-14 Mar-14 Jun-13 Promoter 50.8 50.8 50.9 DII 8.5 8.4 9.9 FII 20.5 20.1 19.5 Others 20.3 20.7 19.8 Notes: FII includes depository receipts Stock performance (1-year)
  • 6. 12 August 2014 6 Britannia Industries Financials and valuations Income statement (INR Million) Y/E Mar 2014 2015E 2016E 2017E Net Sales 62,321 71,470 82,683 98,062 Change (%) 12.0 14.7 15.7 18.6 EBITDA 5,961 7,047 8,369 10,117 EBITDA Margin (%) 9.5 9.7 10.0 10.2 Depreciation 634 723 828 986 EBIT 5,328 6,324 7,541 9,131 Interest 54 43 39 32 Other Income 353 380 400 450 Extraordinary items 0 0 0 0 PBT 5,626 6,661 7,901 9,549 Tax 1,795 2,065 2,449 3,151 Tax Rate (%) 31.9 31.0 31.0 33.0 Reported PAT 3,832 4,596 5,452 6,398 Adjusted PAT 3,698 4,596 5,451 6,397 Change (%) 58.1 24.3 18.6 17.4 Min. Int. & Assoc. Share 0 0 0 0 Adj Cons PAT 3,832 4,596 5,452 6,398 Balance sheet (INR Million) Y/E Mar 2014 2015E 2016E 2017E Share Capital 239 239 239 239 Reserves 8,761 10,687 12,970 15,650 Net Worth 9,000 10,926 13,209 15,889 Debt 843 1,501 308 308 Deferred Tax 4 4 4 4 Total Capital Employed 9,843 12,427 13,517 16,197 Gross Fixed Assets 8,893 10,143 11,643 13,643 Less: Acc Depreciation -4,556 -5,279 -6,107 -7,093 Net Fixed Assets 4,337 4,864 5,536 6,550 Capital WIP 250 250 250 250 Investments 3,799 6,123 6,675 8,425 Current Assets 9,952 11,340 12,811 14,803 Inventory 5,037 5,718 6,201 7,355 Debtors 908 1,026 1,180 1,391 Cash & Bank 1,744 2,151 2,800 3,200 Loans & Adv, Others 2,264 2,446 2,630 2,858 Curr Liabs & Provns 8,499 10,154 11,758 13,835 Curr. Liabilities 6,043 6,968 7,978 9,330 Provisions 2,456 3,187 3,780 4,505 Net Current Assets 1,453 1,186 1,053 968 Total Assets 9,843 12,427 13,517 16,197 E: MOSL Estimates Ratios Y/E Mar 2014 2015E 2016E 2017E Basic (INR) EPS 31.0 38.5 45.6 53.6 Cash EPS 37.4 44.5 52.6 61.8 Book Value 75.3 91.5 110.6 133.0 DPS 14.8 19.2 22.8 26.8 Payout (incl. Div. Tax.) 53.7 58.1 58.1 58.1 Valuation(x) P/E 37.4 30.1 25.3 21.6 Cash P/E 30.9 26.0 22.0 18.7 Price / Book Value 15.4 12.6 10.5 8.7 EV/Sales 2.1 1.8 1.6 1.3 EV/EBITDA 22.7 18.9 15.6 12.7 Dividend Yield (%) 1.3 1.7 2.0 2.3 Profitability Ratios (%) RoE 46.4 46.1 45.2 44.0 RoCE 58.7 56.8 58.1 61.5 Turnover Ratios (%) Asset Turnover (x) 6.9 6.5 6.4 6.7 Debtors (No. of Days) 5.3 5.2 5.2 5.1 Inventory (No. of Days) 29.1 28.9 27.1 27.1 Creditors (No. of Days) 35.3 35.8 35.8 35.6 Leverage Ratios (%) Net Debt/Equity (x) 0.1 0.1 0.0 0.0 Cash flow statement (INR Million) Y/E Mar 2014 2015E 2016E 2017E OP/(Loss) before Tax 4,637 5,590 6,795 8,439 Depreciation 571 634 723 828 Others 353 380 400 450 Interest 54 43 39 32 Direct Taxes Paid 1,795 2,065 2,449 3,151 (Inc)/Dec in Wkg Cap 644 -674 -782 -485 CF from Op. Activity 3,068 5,171 6,212 7,019 (Inc)/Dec in FA & CWIP 1,250 1,250 1,500 2,000 (Pur)/Sale of Invt -755 2,324 551 1,751 Others 133 0 1 1 CF from Inv. Activity 629 3,574 2,052 3,752 Inc/(Dec) in Net Worth 0 0 0 0 Inc / (Dec) in Debt 40 658 -1,193 0 Interest Paid 0 0 0 0 Divd Paid (incl Tax) 1,189 2,058 2,670 3,168 CF from Fin. Activity -1,418 -1,189 -3,510 -2,868 Inc/(Dec) in Cash 1,021 408 649 400 Add: Opening Balance 722 1,744 2,151 2,800 Closing Balance 1,744 2,151 2,800 3,200
  • 7. 12 August 2014 7 Britannia Industries N O T E S
  • 8. 12 August 2014 8 Britannia Industries Disclosures This research report has been prepared by MOSt to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its affiliated company(ies). This report is for personal information of the select recipient and does not construe to be any investment, legal or taxation advice to you. This research report does not constitute an offer, invitation or inducement to invest in securities or other investments and Motilal Oswal Securities Limited (hereinafter referred as MOSt) is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other person in any form. This report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. MOSt and its affiliates are a full-service, integrated investment banking, investment management, brokerage and financing group. We and our affiliates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department Our research professionals provide important input into our investment banking and other business selection processes. Investors should assume that MOSt and/or its affiliates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material and that the research professionals who were involved in preparing this material may participate in the solicitation of such business. The research professionals responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. Our research professionals are paid in part based on the profitability of MOSt which include earnings from investment banking and other business. MOSt generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, MOSt generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all o the foregoing, among other things, may give rise to real or potential conflicts of interest . MOSt and its affiliated company(ies), their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Unauthorized disclosure, use, dissemination or copying (either whole or partial) of this information, is prohibited. The person accessing this information specifically agrees to exempt MOSt or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOSt or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOSt or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays. The information contained herein is based on publicly available data or other sources believed to be reliable. Any statements contained in this report attributed to a third party represent MOSt’s interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. This Report is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. While we would endeavor to update the information herein on reasonable basis, MOSt and/or its affiliates are under no obligation to update the information. Also there may be regulatory, compliance, or other reasons that may prevent MOSt and/or its affiliates from doing so. MOSt or any of its affiliates or employees shall not be in any way responsible and liable for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. MOSt or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations. Recipients who are not institutional investors should seek advice of their independent financial advisor prior to taking any investment decision based on this report or for any necessary explanation of its contents. MOSt and/or its affiliates and/or employees may have interests/positions, financial or otherwise in the securities mentioned in this report. To enhance transparency, MOSt has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. Disclosure of Interest Statement BRITANNIA INDUSTRIES LTD  Analyst ownership of the stock No Analyst Certification The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The research analysts, strategists, or research associates principally responsible for preparation of MOSt research receive compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues. Regional Disclosures (outside India) This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOSt & its group companies to registration or licensing requirements within such jurisdictions. For U.K. This report is intended for distribution only to persons having professional experience in matters relating to investments as described in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (referred to as "investment professionals"). This document must not be acted on or relied on by persons who are not investment professionals. Any investment or investment activity to which this document relates is only available to investment professionals and will be engaged in only with such persons. For U.S. Motilal Oswal Securities Limited (MOSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition MOSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account. For Singapore Motilal Oswal Capital Markets Singapore Pte Limited is acting as an exempt financial advisor under section 23(1)(f) of the Financial Advisers Act(FAA) read with regulation 17(1)(d) of the Financial Advisors Regulations and is a subsidiary of Motilal Oswal Securities Limited in India. This research is distributed in Singapore by Motilal Oswal Capital Markets Singapore Pte Limited and it is only directed in Singapore to accredited investors, as defined in the Financial Advisers Regulations and the Securities and Futures Act (Chapter 289), as amended from time to time. In respect of any matter arising from or in connection with the research you could contact the following representatives of Motilal Oswal Capital Markets Singapore Pte Limited: Anosh Koppikar Kadambari Balachandran Email:anosh.Koppikar@motilaloswal.com Email : kadambari.balachandran@motilaloswal.com Contact(+65)68189232 Contact: (+65) 68189233 / 65249115 Office Address:21 (Suite 31),16 Collyer Quay,Singapore 04931 Motilal Oswal Securities Ltd Motilal Oswal Tower, Level 9, Sayani Road, Prabhadevi, Mumbai 400 025 Phone: +91 22 3982 5500 E-mail: reports@motilaloswal.com